In patients with diabetes, multiple studies have reported that treatment with MR blockers [87, 88], ARBs [89, 90], ACE inhibitors [90], or a direct renin inhibitor [91] is associated with an increase in potassium levels and a risk of severe hyperkalemia in a small number of patients. The gene discussed is NR3C2; the disease is diabetes mellitus.